(The Epoch Times)—Prescription drugs cost more in the United States than anywhere else in the world. President Donald Trump and some bipartisan senators want to change that.
Trump has so far issued several actions related to prescription drug prices. The latest, announced May 12, is a Most Favored Nation Prescription Drug policy, requiring pharmaceutical companies to offer their lowest price to U.S. customers.
An earlier order aimed to ensure that the middlemen in the drug supply chain can’t hold on to rebates provided by pharmaceutical companies and instead must pass savings on to Medicare beneficiaries.
In all, the president has taken at least a dozen actions to reduce prescription drug costs, while no less than nine Senate bills aim for the same results.
Some of these ideas have been introduced before.
Trump’s Most Favored Nation pricing plan was introduced near the end of his first term.
The plan was stalled by court challenges, and President Joe Biden dropped it shortly after taking office.
A plan to make vendors pass manufacturer discounts on to Medicare beneficiaries was proposed in 2020. Biden rescinded it before it took effect.
There have been modest successes, including a pilot program begun by Trump in 2020 to cap insulin costs for Medicare Part B beneficiaries at $35 per month. At the time, a single vial of insulin cost about $100 in the United States.
That program was a success, and the idea was later broadened to include all Medicare beneficiaries through the Inflation Reduction Act of 2022. By 2024, most major drug companies had voluntarily limited out-of-pocket expenses for insulin for all U.S. customers to $35.
Yet Americans still pay nearly three times as much for prescription medication as any peer nation, often even more.
Trulicity, a medication for Type 2 diabetics, was listed for $67 in France, according to a 2021 Government Accountability Report. In the United States, it cost $798.
Meanwhile, Remlivid, an oral cancer medication, was listed for $4,723 in Australia. In the United States, it was listed at almost five times that price: $22,048.
Why? One answer is that other governments leverage the power of their national health plans to control pricing, while the United States lacks a comprehensive national prescription drug strategy.
The solution, according to at least one senator, is to stop putting patches on a broken system and take a comprehensive approach to regulating the entire pharmaceutical supply chain.
How Others Do It
Some nations can negotiate low prices for prescription drugs because they have national health care plans, which gives them near complete control over the drug market. Here’s how that works for some, according to the Government Accountability Office.
Australia
Australia has a national health care system that is partly administered by state, territorial, and local governments.
Prescription drug pricing is set at the national level, starting with an assessment of the drug’s value. That assessment is made by Australia’s independent Pharmaceutical Benefits Advisory Committee, which evaluates new drugs for cost-effectiveness and may recommend them for inclusion on the list of approved medications under the national health plan.
That decision is made by Australia’s national minister of health, who then negotiates with the manufacturer to determine a price. Among other considerations, the health minister evaluates the impact of adding the drug on the country’s budget.
Canada
Canada keeps prescription prices low in two ways. First, Canada’s federal government sets a maximum allowable price for each medication. The government bases this price, in part, on the therapeutic value of the drug. That value may be higher if the drug is the first of its kind, or lower if there are similar drugs already on the market.
Second, the country’s 13 provincial and territorial health plans negotiate pricing jointly with manufacturers, combining the power of their respective markets.
France
France has a national health care system that includes prescription drugs.
The French government negotiates prices with manufacturers based on an assessment of the therapeutic value of the drug. The country also places a cap on total prescription spending.
The Drawbacks
These arrangements significantly lower prescription costs for the government and for patients. But there are drawbacks.
When a U.S. insurance company can’t negotiate an acceptable price from a drug manufacturer, the insurer may choose not to cover the drug. However, another company will often cover it, so patients still have options.
However, when a drug is omitted from a national health plan, it may be more difficult to find it or afford it anywhere in that country.
For example, Signifor, a drug used to treat hormonal diseases, was not available in Ontario, Canada, according to a 2021 study by the Government Accountability Office. Some forms of diabetes drug Trulicity were not available in Australia. Cancer medicine Revlimid 5 milligram and 10 milligram capsules were not available in France.
Or, drugs left off the national coverage list may still be available, but at a higher price.
Drug shortages are another problem.
In countries with national health plans, pharmaceutical companies have less incentive to ensure supply. Companies will favor markets where there is more potential for profit.
“[Drug] shortages are a natural outcome of imposing prices divorced from free market processes,” Jeremy Nighohossian, a senior fellow at the Competitive Enterprise Institute, a libertarian think tank, told The Epoch Times.
Stephen Ubl, president and CEO of Pharmaceutical Research and Manufacturers of America, said, “Importing foreign prices from socialist countries would be a bad deal for American patients and workers,” in a May 12 response to Trump’s plan.
“It would mean less treatments and cures and would jeopardize the hundreds of billions our member companies are planning to invest in America—threatening jobs, hurting our economy and making us more reliant on China for innovative medicines.”
The US System
In the United States, various government agencies, private health plans, and commercial insurance companies each take their own approach to controlling prescription costs.
The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices with insurance companies.
Those negotiations resulted in price reductions of roughly 40 to 80 percent for 10 medications, effective in 2026. Fifteen more discounted drug prices will go into effect in 2027.
However, all these medications are of a lesser-expensive type known as small-molecule drugs, according to C. Michael White of the University of Connecticut School of Pharmacy. None of the more costly large-molecule drugs used to treat cancer and other diseases were discounted.
White thinks greater savings are possible. “Private insurers negotiate the price of all drugs with manufacturers, so why is the federal government only negotiating a handful each year?” he told The Epoch Times.
Insurers generally outsource prescription drug negotiations to pharmacy benefit managers. These companies both negotiate prices and process pharmacy claims for insurers.
In theory, this should result in lower prices for consumers and greater efficiency for insurers, but that’s not always the case, according to Sen. Chuck Grassley (R-Iowa).
Pharmacy benefit managers “exercise growing influence on prescription drug supply chain,” Grassley told a Senate Judiciary Committee hearing on pharmaceutical competition May 13.
“As the middleman, they determine what medications a patient can use and how much the patient pays at the pharmacy counter.”
While pharmacy benefit managers claim to lower costs, Grassley pointed to what he called “opaque” business practices, saying the profits made by pharmacy benefit managers have increased “in ways that don’t add up based on the services they provide.”
Grassley has introduced a bill to require pharmacy benefit managers to be more transparent about drug prices and service fees.
Patches Versus Holistic Approach
Policymakers generally agree that high drug prices are a problem, yet there is no consensus on how to solve it.
Sens. Josh Hawley (R-Mo.) and Peter Welch (D-Vt.) introduced legislation on May 5 to accomplish something similar to Trump’s plan, compelling drug makers to offer lower prices in the United States.
The Republican budget reconciliation bill now being debated also includes provisions to make drug pricing more transparent in the Medicaid system.
This scattershot approach won’t work, according to Sen. Thom Tillis (R-N.C.), who believes Congress must step back and evaluate the entire medication supply chain to decide “how we ultimately address this problem.”
“All these other things are short-sighted, unsustainable measures that are not going to produce the result,” Tillis said on May 13.
Under Trump’s Most Favored Nation Prescription Drug policy, the first round of target prices is set to be delivered by Health and Human Services to pharmaceutical makers by June 11, aiming to align American drug prices with those of comparably developed nations.
Bypass Big Tech Censors
Safeguarding Your American Dream: Discover the Power of America First Healthcare
In today’s economy, healthcare costs remain one of the biggest threats to financial stability and family security. Americans work hard to build a better life, yet rising medical expenses can quickly erode savings, force tough trade-offs, and even push families toward debt or bankruptcy. Medical bills continue to rank as the leading cause of personal bankruptcy in the United States, with millions facing underinsurance or unexpected out-of-pocket burdens that no one plans for. Many turn to government-run marketplace plans under the Affordable Care Act, hoping for relief, only to discover that what appears affordable on paper often delivers higher long-term costs, limited real protection, and coverage that may not align with personal values or family needs.
America First Healthcare stands out as a private insurance agency dedicated to helping conservatives and families secure better coverage and better rates through customized, values-aligned options. By conducting free insurance reviews, the agency uncovers hidden gaps in existing policies and connects clients with private alternatives that emphasize personal responsibility, small-government principles, and genuine affordability—often delivering up to 20% savings while providing stronger protection for the American Dream.
The allure of marketplace plans is easy to understand: open enrollment periods, premium tax credits for many households, and the promise of “comprehensive” benefits mandated by law. Yet recent data reveals a different reality, especially after the expiration of enhanced premium subsidies at the end of 2025. Enrollment for 2026 dropped by more than one million people compared to the prior year, with many shifting to lower-tier bronze plans to keep monthly premiums manageable.
These plans feature significantly higher deductibles—averaging around $7,500 nationally—and greater cost-sharing requirements. Families who once paid modest amounts after subsidies now face average premium increases of $65 or more per month, even as they accept plans that leave them responsible for thousands in upfront costs before meaningful coverage kicks in.
High deductibles create a dangerous barrier to care. Studies show that people in such plans are less likely to seek timely treatment for chronic conditions, attend preventive screenings, or fill necessary prescriptions. A seemingly minor illness or injury can balloon into major expenses when patients delay care until problems worsen. For a family of four, a single hospitalization, cancer diagnosis, or unexpected surgery can easily exceed the deductible, triggering coinsurance and out-of-pocket maximums that still leave substantial bills. One recent analysis noted that some proposed changes could push family deductibles toward $31,000 in future years, further exposing households to financial risk.
Beyond the numbers, marketplace plans often carry structural limitations. Coverage for certain critical services may include waiting periods or narrower networks that restrict access to preferred doctors and specialists. Preventive care is required to be covered without cost-sharing, but everything else—lab work, imaging, specialist visits, or ongoing treatment—typically waits until the deductible is met. This reactive model contrasts sharply with the proactive, holistic approach many families prefer, especially those focused on wellness, early intervention, and maintaining health to enjoy life rather than merely reacting to illness.
Values alignment represents another growing concern. Government-influenced plans operate within a framework shaped by federal mandates and political priorities that may not reflect conservative principles of limited government, personal freedom, and ethical stewardship. Families who want to direct their healthcare dollars toward providers and benefits that honor traditional values sometimes find marketplace options feel misaligned, forcing a compromise between affordability and conviction.
Private alternatives, by contrast, offer year-round flexibility without the restrictions of open enrollment windows. Independent agents can shop across a wider range of carriers to design plans tailored to specific family needs—whether that means lower deductibles for frequent medical users, broader provider networks, or add-ons that support wellness and preventive services from day one. Clients frequently report more stable premiums that do not automatically escalate each year, along with genuine cost savings once the full picture of deductibles, copays, and coverage depth is considered.
Take the experience of real families who made the switch. Amanda C. shared that her new plan felt “way better” than what she had through the marketplace. Johnny Y. noted his previous coverage kept increasing annually until he found a more stable private option. Sofia S. expressed delight with her plan and began recommending it to others. These stories echo a common theme: when families move beyond one-size-fits-all government marketplaces, they often discover customized protection that better safeguards both health and finances.
Founder Jordan Sarmiento’s own journey underscores the stakes. In 2021, a six-day hospitalization generated a $95,000 bill. Under a well-structured private “Conservative Care Coverage” plan, his out-of-pocket responsibility would have been just $500. That stark difference illustrates how thoughtful planning and private options can prevent a medical event from becoming a financial catastrophe.
Practical steps exist for anyone questioning their current coverage. Start with a no-obligation review of your existing policy to identify gaps—high deductibles, limited critical-care benefits, or escalating premiums. Compare total projected costs (premiums plus potential out-of-pocket expenses) rather than monthly premiums alone. Consider family health history, anticipated needs, and lifestyle priorities. Private agencies can present side-by-side options that include stronger wellness incentives, broader access, and plans built on shared values of self-reliance and freedom.
In an era when healthcare inflation continues to outpace general cost-of-living increases, relying solely on marketplace solutions carries growing risk. Families who proactively explore private alternatives frequently achieve meaningful savings while gaining peace of mind that their coverage truly works when needed most.
America First Healthcare makes this exploration straightforward through its free review process. Families and individuals receive personalized guidance to close coverage holes, reduce unnecessary expenses, and secure plans that align with conservative principles—protecting wallets, health, and the American Dream without government overreach. Many who complete a review discover they can enjoy better benefits for less, often saving up to 20% while gaining the customization and stability that marketplace plans struggle to deliver.
Ultimately, protecting your family’s future requires looking beyond the marketing of “affordable” government options. By understanding the long-term costs hidden in high deductibles, shifting coverage tiers, and values mismatches, Americans can make empowered choices. Private, values-driven insurance offers a smarter path—one that rewards diligence, supports wellness, and delivers real security. For those ready to move beyond the limitations of traditional marketplace plans, a simple review can reveal options designed to serve families, not bureaucracies. The American Dream thrives when individuals and families retain control over their healthcare decisions, and thoughtful private coverage plays a vital role in making that possible.